Clinical trial
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
NCT00005842 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005842 |
|---|---|
| Title | Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer |
| Official title | A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, tipifarnib |
| Enrollment | 24 |
| Start date | Jun 1, 2000 |
| Primary completion | Feb 1, 2004 |
| First posted | Apr 26, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: